Cytosorbents Corp - Common Stock, par value $0.001 per share (CTSO) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
CTSO on Nasdaq
Shares outstanding
65,881,982
Price per share
$0.63
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
16,334,989
Total reported value
$15,255,905
% of total 13F portfolios
0%
Share change
-76,161
Value change
-$76,175
Number of holders
48
Price from insider filings
$0.63
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cytosorbents Corp - Common Stock, par value $0.001 per share (CTSO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SATTERFIELD THOMAS A JR 6.6% $3,998,867 3,998,867 Thomas A. Satterfield, Jr. 13 Jan 2025
Avenue Venture Opportunities Fund, L.P. 5.7% $4,356,117 3,755,273 Avenue Capital Management II, L.P. 26 Jun 2024
AVENIR CORP 5.7% $3,093,946 3,093,946 AVENIR CORP 31 Dec 2024
Skylands Capital, LLC 4.8% -6% $3,002,702 +$221,080 3,002,702 +7.9% Skylands Capital, LLC 31 Mar 2025
VANGUARD GROUP INC 3.1% -57% $1,949,551 -$1,949,551 1,949,551 -50% The Vanguard Group 31 Mar 2025

As of 30 Sep 2025, 48 institutional investors reported holding 16,334,989 shares of Cytosorbents Corp - Common Stock, par value $0.001 per share (CTSO). This represents 25% of the company’s total 65,881,982 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cytosorbents Corp - Common Stock, par value $0.001 per share (CTSO) together control 24% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
AVENIR CORP 7.7% 5,082,838 +0.48% 0.49% $4,747,879
VANGUARD GROUP INC 3.3% 2,204,294 +3.7% 0% $2,058,811
Skylands Capital, LLC 3.2% 2,127,265 -19% 0.27% $1,987,078
NEUBERGER BERMAN GROUP LLC 2.4% 1,597,998 +0.4% 0% $1,490,906
CM Management, LLC 2% 1,288,128 +3.1% 1% $1,203,240
BlackRock, Inc. 1.2% 764,809 +2.6% 0% $714,408
Sargent Investment Group, LLC 1.1% 738,700 -1% 0.1% $690,020
GEODE CAPITAL MANAGEMENT, LLC 0.91% 601,451 0% 0% $561,978
CIBC Private Wealth Group LLC 0.26% 172,649 0% 0% $161,271
STATE STREET CORP 0.24% 159,293 0% 0% $148,796
RENAISSANCE TECHNOLOGIES LLC 0.2% 134,805 +16% 0% $125,921
OSAIC HOLDINGS, INC. 0.2% 130,419 0% 0% $122,444
UBS Group AG 0.17% 115,203 -5.8% 0% $107,600
GSA CAPITAL PARTNERS LLP 0.17% 112,217 0.01% $105,000
RAYMOND JAMES FINANCIAL INC 0.17% 108,721 +0.12% 0% $101,556
MORGAN STANLEY 0.16% 107,256 +1.8% 0% $100,188
NWF Advisory Services Inc. 0.16% 104,139 0% 0.01% $97,274
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.15% 98,221 -26% 0% $91,748
NORTHERN TRUST CORP 0.14% 91,560 0% 0% $85,526
Key Client Fiduciary Advisors, LLC 0.12% 78,457 0% 0.02% $73,287
CITADEL ADVISORS LLC 0.1% 65,690 0% $61,361
Kestra Advisory Services, LLC 0.1% 64,528 -9% 0% $60,276
GOLDMAN SACHS GROUP INC 0.09% 60,552 +29% 0% $56,562
Waverly Advisors, LLC 0.08% 55,556 0% $51,895
STIFEL FINANCIAL CORP 0.07% 48,000 0% 0% $44,837

Institutional Holders of Cytosorbents Corp - Common Stock, par value $0.001 per share (CTSO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 16,334,989 $15,255,905 -$76,175 $0.93 48
2025 Q2 16,439,150 $20,747,017 -$475,509 $1.28 43
2025 Q1 16,936,549 $16,946,108 +$1,621,893 $1.00 47
2024 Q4 15,229,954 $14,042,830 -$1,250,901 $0.91 49
2024 Q3 16,412,746 $24,619,301 -$178,843 $1.50 51
2024 Q2 16,409,887 $11,536,914 -$649,270 $0.70 44
2024 Q1 17,531,124 $16,641,395 -$401,273 $0.95 47
2023 Q4 1,874,799 $2,077,611 +$331,436 $1.11 2
2023 Q3 15,170,414 $28,514,495 -$163,915 $1.88 50
2023 Q2 15,184,349 $54,498,911 +$124,445 $3.59 57
2023 Q1 15,119,779 $51,075,434 +$1,744,392 $3.37 56
2022 Q4 14,558,956 $22,523,713 -$221,659 $1.55 46
2022 Q3 12,923,308 $17,569,835 -$1,322,378 $1.36 48
2022 Q2 14,214,992 $31,135,658 -$1,585,719 $2.19 62
2022 Q1 15,346,012 $48,926,184 +$169,672 $3.19 77
2021 Q4 17,598,292 $73,758,808 -$7,843,928 $4.19 87
2021 Q3 18,366,121 $149,207,914 +$7,089,192 $8.12 94
2021 Q2 17,035,924 $128,690,236 -$26,132 $7.55 95
2021 Q1 17,052,104 $148,903,944 -$1,689,624 $8.68 91
2020 Q4 17,036,789 $135,778,028 +$2,849,462 $7.97 86
2020 Q3 17,141,271 $136,709,701 +$46,397,364 $7.98 92
2020 Q2 11,219,987 $111,120,626 +$14,242,674 $9.90 88
2020 Q1 9,902,410 $76,504,098 +$8,993,388 $7.73 78
2019 Q4 8,896,772 $34,247,814 +$1,440,928 $3.85 68
2019 Q3 8,407,364 $42,286,266 -$822,168 $5.03 63
2019 Q2 8,390,426 $55,460,404 +$428,120 $6.61 63
2019 Q1 8,362,955 $63,304,572 -$402,224 $7.57 68
2018 Q4 8,654,446 $69,912,146 +$1,135,242 $8.08 82
2018 Q3 8,196,875 $105,728,460 +$5,040,834 $12.90 78
2018 Q2 7,720,645 $88,020,578 +$46,323,531 $11.40 71
2018 Q1 3,901,828 $27,508,000 +$5,641,190 $7.05 44
2017 Q4 3,181,141 $20,606,078 +$4,751,567 $6.50 42
2017 Q3 2,481,878 $15,385,000 +$3,763,177 $6.20 31
2017 Q2 1,938,263 $8,335,000 -$2,211,460 $4.30 30
2017 Q1 2,431,298 $10,938,000 +$4,446,292 $4.50 32
2016 Q4 1,593,388 $8,683,000 +$49,090 $5.45 36
2016 Q3 1,568,958 $10,038,360 -$1,210,440 $6.40 34
2016 Q2 1,773,199 $8,063,000 +$386,283 $4.55 33
2016 Q1 1,376,353 $5,391,447 -$36,175 $3.92 31
2015 Q4 1,375,701 $7,660,000 -$95,334 $5.57 38
2015 Q3 1,350,065 $8,514,000 +$664,078 $6.30 32
2015 Q2 1,222,430 $7,505,037 +$715,848 $6.14 28
2015 Q1 901,201 $11,887,236 +$7,837,553 $13.19 26
2014 Q4 394,240 $3,921,376 +$1,051,377 $9.96 9